Blog

Nelson Advisors has been referenced in Doctor Care Anywhere's article 'The thinking behind our Medicspot acquisition - and why it’s different'.Source: <a href="https://investors.doctorcareanywhere.com/activity-updates/rvWLMP-why-we-moved-into-weight-management">https://investors.doctorcareanywhere.com/activity-updates/rvWLMP-why-we-moved-into-weight-management</a>Something unusual has happened in UK healthcare over the last three years. GLP-1 weight-loss treatment, barely used by consumers in 2022, is now one of the fastest-growing areas of private healthcare in the country. Around 3 million UK adults use these medications, the vast majority paying privately, since the NHS reaches only a narrow eligibility group (PwC, 2026). PwC expects that number to more than double as pill versions arrive.You’ll recognise this pattern wherever you’re reading from. In Australia, more than 400,000 people already pay privately for these drugs (there’s still no PBS subsidy for the obesity indication), and Eucalyptus, the group behind Pilot and Juniper, just sold to Hims &amp; Hers forUS$1.15 billion, near 4.6 times revenue, with its UK business now bigger than its Australian one. The market has put a very large number on this category. That’s worth keeping in mind against what we paid.The dealIn May we acquired Medicspot, a direct-to-consumer GLP-1 weight-loss service founded in 2016:• &nbsp; &nbsp; &nbsp; £850,000 in cash, paid on completion - no earn-out, no deferred consideration.• &nbsp; &nbsp; &nbsp; £5.3 million revenue in the twelve months to March 2026, broadly breakeven on EBITDA.• &nbsp; &nbsp; &nbsp; Roughly 0.16 times sales - a fraction of the ~4.6 times revenue Eucalyptus sold for.• &nbsp; &nbsp; &nbsp; Funded entirely from existing cash.Medicspot and Eucalyptus aren’t directly comparable, but the gap illustrates the kind of asymmetry we look for: a validated, fast-growing category, bought before Medicspot has contributed a full year of revenue or any cross-sell benefit.Healthcare.digital (2026) Global Health Convergence: Analysis of the $1.15 Billion Acquisition of Eucalyptus by Hims &amp; Hers Health. Available at: <a href="https://www.healthcare.digital/single-post/global-health-convergence-analysis-of-the-1-15-billion-acquisition-of-eucalyptus-by-hims-hers-he">https://www.healthcare.digital/single-post/global-health-convergence-analysis-of-the-1-15-billion-acquisition-of-eucalyptus-by-hims-hers-he</a>.

Nelson Advisors referenced in Doctor Care Anywhere's article 'The thinking behind our Medicspot acquisition - and why it’s different'

Nelson Advisors has been referenced in YouTrust's article 'How to Update a Shareholder Agreement After a Funding Round'.Source: <a href="https://youtrust.com/blog/how-to-update-shareholder-agreement-after-funding-round">https://youtrust.com/blog/how-to-update-shareholder-agreement-after-funding-round</a>Anti-Dilution Protections and Founder VestingInvestors in later rounds often negotiate anti-dilution clauses protecting the value of their investment if future shares are issued at a lower price. The most common forms are broad-based weighted average and full ratchet, each with significantly different economic consequences for founders. Separately, if founders are still vesting, the agreement should confirm whether the new round affects the vesting schedule, and good leaver and bad leaver provisions should be reviewed to ensure they reflect the current team composition.<a href="https://nelsonadvisors.co.uk/blog/understanding-anti-dilution-protection-clauses-for-venture-capitalists--a-cheat-sheet-for-healthtech-founders" data-mce-selected="inline-boundary">﻿https://nelsonadvisors.co.uk/blog/understanding-anti-dilution-protection-clauses-for-venture-capitalists--a-cheat-sheet-for-healthtech-founders﻿</a> &nbsp;

Nelson Advisors referenced in YouTrust's article 'How to Update a Shareholder Agreement After a Funding Round'

Nelson Advisors has been referenced in Tandem Health's article 'Clinical AI scribe alternatives for European healthcare'.Source: <a href="https://tandemhealth.ai/da/ressourcer/indsigt/clinical-ai-scribe-alternatives-for-european-healthcare" data-mce-href="https://tandemhealth.ai/da/ressourcer/indsigt/clinical-ai-scribe-alternatives-for-european-healthcare">https://tandemhealth.ai/da/ressourcer/indsigt/clinical-ai-scribe-alternatives-for-european-healthcare</a>The NHS 10-Year Health Plan, published in July 2025, explicitly identifies AI scribes as a core component of the shift to a digitally-driven care model. NHS England's ambient scribing guidance provides a reference framework for evaluating tools in the UK public sector context.Private healthcare organisations may have greater flexibility in procurement timelines and vendor selection, but should not treat regulatory compliance as optional. Key differences in priority include:Faster deployment timelines may be feasible without national framework constraints Specialty coverage breadth matters more when supporting a diverse range of consultants Billing integration and private coding schemes, such as procedure codes for insurers, may be relevant Patient experience considerations, particularly around consent and data use, remain significant<a href="https://nelsonadvisors.co.uk/blog/ambient-voice-technology-and-the-nhs-10-year-plan--strategy--future-applications--key-suppliers--funding-and-regulatory-landscape">https://nelsonadvisors.co.uk/blog/ambient-voice-technology-and-the-nhs-10-year-plan--strategy--future-applications--key-suppliers--funding-and-regulatory-landscape﻿</a>

Nelson Advisors referenced in Tandem Health's article 'Clinical AI scribe alternatives for European healthcare'

By the time a sub-sector has a Kearney report, the entry multiple has already moved. Here's what's crossing our desk now. &nbsp;&nbsp; The macroeconomic landscape for European healthcare technology has undergone a structural transformation. The speculative capital deployment into unintegrated point solutions that characterised the zero-interest-rate era has given way to an environment focused on unit economics, real-world clinical evidence, regulatory defensibility and deep workflow integration. The European HealthTech market is projected to expand from $96.68 Billion in 2025 to over $222 Billion by 2030, representing a compound annual growth rate (CAGR) of 18.11%. This long-term expansion is driven by severe systemic pressures: acute clinical labor shortages, aging demographics and administrative burdens that consume nearly half of a clinician’s working day. &nbsp;&nbsp; Within this landscape, proprietary deal sourcing requires looking beyond conventional Health IT categories. Private equity firms seeking outsized returns must identify sub-sectors before institutional consensus drives valuation expansion. &nbsp;&nbsp; Nelson Advisors' deal flow screening highlights five frontier sub-sectors currently moving through middle-market deal desks that present immediate platform-building and growth capital deployment opportunities within the €25 Million to €250 Million Enterprise Value (EV) window.Click here to read the full report <a href="https://www.healthcare.digital/single-post/five-emerging-healthtech-sub-sectors-private-equity-should-be-screening-now-before-the-multiples-mov">https://www.healthcare.digital/single-post/five-emerging-healthtech-sub-sectors-private-equity-should-be-screening-now-before-the-multiples-mov</a>

Five Emerging HealthTech Sub Sectors Private Equity Should Be Screening Now Before the Multiples Move

Buying at 6x EBITDA and selling at 10x to 14x EBITDA only works if the platform actually integrates; in HealthTech, most don't. In the European lower mid-market, private equity sponsors frequently default to traditional roll-up playbooks perfected in physical healthcare services, such as dental networks, veterinary chains, or primary care clinics. In physical services consolidation, value creation relies on centralising back-office functions, such as procurement, payroll, billing and scheduling, while leaving local clinical operations largely autonomous. Applying this surface level roll-up strategy to clinical software and HealthTech assets repeatedly triggers severe operational stagnation and value destruction. &nbsp;&nbsp; Unlike physical clinic branches, clinical software assets cannot exist as autonomous, siloed outposts under a shared corporate umbrella. Digital health assets operate within highly complex, tightly coupled clinical workflows, heterogeneous data environments, and stringently enforced regulatory frameworks. When acquired software assets fail to integrate at the codebase, data schema, and quality management levels, expected cost and revenue synergies evaporate. Instead, platforms become clogged with compounding technical debt, escalating customer acquisition costs (CAC), provider pushback and elevated customer churn. &nbsp;&nbsp; Despite these operational risks, private equity commitment to European healthcare technology remains intense. Sponsor buyout volume in European healthcare surged by 276% year-over-year to €29.6 Billion, pushing total transaction value to €31.8 Billion across the first half of 2025 alone. Driven by massive dry powder reserves and a fundamentally fragmented European market, lower mid-market investors view buy-and-build as their primary strategy for scaling assets with $5 Million to $10 Million in EBITDA. Achieving true multiple arbitrage, however, requires moving beyond financial engineering to master the operational mechanics of clinical software integration, regulatory sequencing and architectural unification.Strategic Guidance for Private Equity Investment Committees and Operating Partners &nbsp;&nbsp; To successfully execute lower mid-market buy-and-build strategies in European HealthTech, private equity sponsors and operating partners should adopt the following operational guidelines: Enforce Technical Due Diligence Before Capital Commitment: Prioritize codebase hygiene and cloud-native architecture over pure top-line revenue scale. Reject platform targets that consist of unintegrated collections of legacy codebases. Ensure the platform asset features open RESTful APIs, modern micro-services and native FHIR/OMOP compatibility prior to executing the initial transaction.Sequence Bolt-Ons by Regulatory Complexity: Structure acquisition schedules to manage operational risk. Acquire low-risk administrative, practice management, and billing software in Year 1 to expand market footprint and compress acquisition costs. Defer high-burden, MDR/IVDR-regulated diagnostic and AI targets to Years 2 and 3, after centralising Quality Management System infrastructure.Unify Go-to-Market Infrastructure Within 90 Days: Eliminate redundant ad spend and agency sprawl immediately following acquisition. Centralising digital marketing and patient acquisition infrastructure prevents CAC multiplication, protecting portfolio EBITDA from margin compression.Convert Regulatory Frameworks into Competitive Moats: Invest early in establishing a centralized Quality Management System compliant with ISO 13485, EU MDR, IVDR, and the EU AI Act. Transforming regulatory compliance into shared platform infrastructure allows the platform to absorb smaller targets efficiently, establishing market entry barriers that command premium multiples at exit.Click here to read the full report <a href="https://www.healthcare.digital/single-post/buy-and-build-in-european-healthtech-a-playbook-for-platform-selection-bolt-on-sequencing-and-mult">https://www.healthcare.digital/single-post/buy-and-build-in-european-healthtech-a-playbook-for-platform-selection-bolt-on-sequencing-and-mult</a> &nbsp;

Playbook for Platform Selection, Bolt-On Sequencing and Multiple Arbitrage: Buy and Build in European HealthTech

Average HealthTech deal size has more than tripled since 2022, but the entry multiples that make a fund's vintage are still found below €250M EV. &nbsp;&nbsp; Global and European healthcare M&amp;A surged in 2025, with global transaction value reaching $546.7 billion, a 38% increase year-over-year. In Europe, private equity healthcare buyout value reached $80.9 billion in 2025 and is projected to surpass $95.0 billion in 2026. Disclosed global healthcare buyout value exceeded $191 billion in 2025, propelled by pent-up capital deployment and large platform transactions exceeding $1 billion in Enterprise Value (EV).&nbsp; &nbsp;&nbsp; However, headline deployment numbers mask a bifurcated market. In the mega-cap space, intense competition among bulge-bracket sponsors and strategic acquirers has driven entry multiples to 15x–25x EBITDA. At these valuations, achieving hurdle rates requires aggressive leverage and near-flawless operational execution. Genuine alpha and upper-quartile Multiple on Invested Capital (MOIC) are concentrated in the lower-to-middle market (LMM): European targets valued between €25 million and €250 million EV, generating €1 million to €10 million in operating EBITDA.&nbsp; &nbsp;&nbsp; These founder-led businesses trade at entry multiples of 10x–14x EBITDA, offering institutional sponsors insulation from competitive public auctions, structural inefficiency in target advisory, and an abundant supply of high-margin assets ready for buy-and-build expansion.Strategic Execution Framework &nbsp;&nbsp; The 2026 European healthcare private equity market presents a clear strategic choice: while mega-cap platform valuations remain crowded and fully priced, lower mid-market HealthTech targets (€25M–€250M EV) offer an attractive risk-adjusted risk/return profile.&nbsp; Sourcing founder-led assets generating €1M to €10M in EBITDA allows sponsors to deploy capital at reasonable entry multiples while capturing structured, multi-turn valuation expansion. &nbsp;&nbsp; To systematically generate alpha in this market segment, private equity sponsors should execute a four-part strategy: &nbsp;&nbsp; Target High Regulatory Moats: Allocate capital to AI-native clinical tools ("glass box" architectures), EHDS data interoperability infrastructure, and MDR-certified clinical hardware where regulatory compliance establishes sustainable competitive barriers.Exploit the Advisory Gap: Build direct sourcing networks and leverage specialized regulatory advisors to identify underbanked, founder-led targets across fragmented European markets before they enter broad sell-side auctions.Drive Buy-and-Build Multiple Arbitrage: Acquire core regional platforms at 10x–12x EBITDA and execute strategic add-on acquisitions at lower multiples to aggregate EBITDA past the institutional €10M threshold.Underwrite Profit-Weighted Growth: Transition portfolio companies from top-line growth metrics toward balanced Rule of 40 performance, targeting high Net Retention Rates (&gt;105%) and strong EBITDA conversion.By bridging the advisory gap, navigating complex regulatory transitions, and consolidating fragmented regional assets into pan-European platforms, mid-market private equity sponsors can generate superior returns and set the benchmark for European healthcare investing in 2026 and beyond.Click here to read the report in full <a href="https://www.healthcare.digital/single-post/the-25m-to-250m-sweet-spot-why-europe-s-healthtech-mid-market-is-where-private-equity-returns-are">https://www.healthcare.digital/single-post/the-25m-to-250m-sweet-spot-why-europe-s-healthtech-mid-market-is-where-private-equity-returns-are</a>

Nelson Advisors

Blog

Nelson Advisors referenced in Doctor Care Anywhere's arti...

Nelson Advisors referenced in YouTrust's article 'How to ...

Nelson Advisors referenced in Tandem Health's article 'Cl...

Five Emerging HealthTech Sub Sectors Private Equity Shoul...

Playbook for Platform Selection, Bolt-On Sequencing and M...

Why Europe's HealthTech Mid-Market Is Where Private Equit...